Shenzhen Hepalink Pharmaceutical Group002399.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 19, 2026, Shenzhen Hepalink Pharmaceutical Group (002399.SZ) trades at a P/E of 67.00x, P/B of 1.15x, P/S of 2.65x, and a dividend yield of 1.72%.
Longitudinal percentile comparison: P/E sits at the 75th percentile over the trailing 10Y window (vs. 78th percentile over 3Y); P/B sits at the 6th percentile over the trailing 10Y window (vs. 19th percentile over 3Y); P/S sits at the 9th percentile over the trailing 10Y window (vs. 24th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 70th percentile within its industry and the 70th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 1.72%, ranking at the 65th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 68.8 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Shenzhen Hepalink Pharmaceutical Group operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 002399 · SZSE: 002399 · 002399
Want the full picture on whether Shenzhen Hepalink Pharmaceutical Group (002399.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 67.00 | ||||||
| P/B (MRQ) | 1.15 | ||||||
| P/S (TTM) | 2.65 | ||||||
| Dividend Yield | 1.72% | ||||||
| Buyback + Div Yield | 1.72% |